TLR5 agonists promote a shift from M2-like macrophages to M1-like macrophages and activate CD8+ T cells, suggesting their potential to enhance the effectiveness of PD-1 inhibitors in mouse tumor models. This evidence concerns the gene CD8A and neoplasm.